期刊文献+

基于循证医学的IVIG管理:院内应用指导意见的建立及流程研究 被引量:5

IVIG management based on evidence-based medicine:research on processes of establishing and applying guidelines in hospital
原文传递
导出
摘要 目的:静脉用人免疫球蛋白(intravenous human immunoglobulin,IVIG)资源紧缺,临床药师运用循证医学手段实现有限资源的合理配置。方法:临床药师积极寻找临床证据,召开多学科临床专家会议,制订静脉用人免疫球蛋白应用指导意见,并确立静脉用人免疫球蛋白管理应用制度,进行标准化流程管理。结果:静脉用人免疫球蛋白应用指导意见中的每项后都附有证据强度和推荐级别;在我院静脉用人免疫球蛋白管理应用制度中明确了临床的权限和药学部门的职责;形成标准化管理流程。结论:临床药师以循证医学为基础对静脉用人免疫球蛋白的临床使用进行有效的调控管理,在静脉用人免疫球蛋白的临床合理使用中发挥了重要作用。 OBJECTIVE Because of the shortage of intravenous human immunoglobulin (IVIG), clinical pharmacists used evidence-based medicine methods to achieve the rational allocation of limited resources. METHODS Clinical pharmacists actively looked for clinical evidences and convened a multidisciplinary clinical expert meeting, to formulate the IVIG application guideline in our hospital, and established IVIG management system in our hospital, standardized the IVIG management process. RESULTS IVIG guideline was developed, the recommendations strength and evidence degree were labeled. The clin- ical departments" rights and pharmacy department's responsibilities were clearly stated in IVIG management system. A stand- ardized management process was established. CONCLUSION Clinical pharmacists can effectively control the IVIG application based on evidence-based medicine, which plays an important role in rational use of IVIG.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2015年第8期734-738,共5页 Chinese Journal of Hospital Pharmacy
关键词 临床药师 循证医学 静脉用人免疫球蛋白 指导意见 clinical pharmacists evidence-based medicine intravenous human irnmunoglobulin guideline
  • 相关文献

参考文献14

  • 1Hartung HP, Mouthon L, Ahmed R, et al. Clinical applica- tions of intravenous immunoglobulins (IVIg) - beyond immu- nodeficiencies and neurology[J]. Clin Exp Immunol, 2009, 158 (Suppl 1) .. 23 33. 被引量:1
  • 2Imbach P, Barandun S, d' Apuzzo V, et al. High-dose intrave- nous gammaglobulin for idiopathic tbrombocytopenic purpura in childhood[J]. Lancet, 1981,1 (8232) : 1228-1231. 被引量:1
  • 3Looney RJ , Huggins J. Use of intravenous imrnunoglobulin G (IVIG)[J]. Best Pract Res Clin Haematol, 2006, 19 (1) : 3- 25. 被引量:1
  • 4Provan D, Nokes JCN, Agrawal S, et al. IVIG Guideline De- velopment Group of the IVIg Expert Working Group Clinical Guidelines for Immunoglobulin Use[M]. 2nd ed. Scotland: Department of Health, 2009. 被引量:1
  • 5Smith SD, Dennington PM, Cooper A. The use of intravenous immunoglobulin for treatment of dermatological conditions in Australia: A review [J]. Australas J Dermatol, 2010,51(4): 227-237. 被引量:1
  • 6Anderson D, Ali K, Blanchette V, et al. Guidelines on the Use of Intravenous Immune Globulin for Hematologic Condi- tions [J]. Transfus Med Rev. 2007, 21(2 Suppl 1):$9-56. 被引量:1
  • 7Orange JS, Hossnye M, Weiler C R, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology[J]. J Allergy Clin Immunol, 2006,117(4 suppl) : 525 553. 被引量:1
  • 8MICROMEDEX~ 2. 0. [OL~ http://www, micromedexsolut- ions. com/micromedex2/librarian. 被引量:1
  • 9Novaretti MC, Dinardo CL. Clinical applications of immuno- globulin:update. [J~. Rev Bras Hematol Hemoter. 2011, 33 (3) :221-230. 被引量:1
  • 10National Blood Authority. Australia. Criteria for the clinical use of intravenous immunoglobulin in Australia. lOLl. 2nd ed. 2012. http://www, blood, gov. au/ivig-criteria. 被引量:1

二级参考文献19

  • 1SINISALO M, AITTONIEMI J, KAYHTY H, et al. Vaccination a- gainst infections in chronic lymphocytic leukemia [ J]. Leuk Lymphoma, 2003, 44(4) :649-652. 被引量:1
  • 2DUHEM C, DICATO M A, RIES F. Side-effects Of intravenous immune globulins [J].Clin Exp Immul, 1994, 97(suppl 1 ) :79- 83. 被引量:1
  • 3ASHLEY A V, VINH C A M, TOYODA M, et al. Safety and ad- verse events profiles of intravenous gammaglobulin products used for immunomodulation: A single-center experience [J]. Clin J Am Soc Nephrol, 2006, 1 : 844-852. 被引量:1
  • 4ORANGE J S, HOSSNY E M, WEILER C R, et al. Use of intravenous immunoglobulin in human isease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology[J]. J Allergy Clin lmmunol, 2006, 117 (4) :525-553. 被引量:1
  • 5HARTUNG H P, MOUTHON L, AHMED R, et al. Clinical ap- plications of intravenous immunoglobulins (IVIg)-beyond immu- nodeficiencies and neurology[ J]. Clin Exp lmmunol, 2009, 158 (suppl 1 ) :23-33. 被引量:1
  • 6ORANGE J S, HOSSNY E M, WEILER C R, et al. Use of intra- venous immunoglobulin in human disease : a review of evidence by members of the Primary Immunodeficiency Committee of the A- merican academy of allergy, Asthma and Immunology[ J]. J Al- lergy Clin Immunol, 2006, 117(4 suppl) :525-553. 被引量:1
  • 7PROVAN D, NOKES TJC, AGRAWAL S, et al. IVIG Guideline Development Group of the IVlg Expert Working Group Clinical Guidelines for Immunoglobulin Use [ M ]. 2nd ed. London : De- partment of, Health, 2008. 被引量:1
  • 8NATIONALIBLOOD AUTHORITY. Australia. Criteria for the clinical use of intravenous immunoglobulin in Australia[ OL]. 20138. http:// www. nba. gov. au/ivig/index, html#/ivig/pdf. 被引量:1
  • 9LEONG H~STACHNIK J,BONK M E, et al. Unlabeled uses of intraven0us immune globulin [ J ]. Am J Health Syst Pharm, 2008,65(19) 1815-1824. 被引量:1
  • 10FDA. IGIV trials for off-label uses recommended by HHC commit- tee on blood safety [ EB/OL~. The Pink Sheet: FDC Report, 1998, 60(4) :18. 被引量:1

共引文献15

同被引文献33

引证文献5

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部